Pharmacy Times

JULY 19, 2025

Malesker, PharmD, FCCP, FCCM, FASHP, BCPS +1 More Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action. 16 At 12 weeks of treatment, placebo-subtracted reductions in sBP were -11.7 Jansen, PharmD Candidate , Mark A. The 50 mg dose achieved a 7.9

HIV Treatment and Prevention Agents 50

HIV Treatment and Prevention Agents Compounding Pharmacies Vaccines Immunization 50

PharmaShots

APRIL 25, 2023

This drug is currently in multiple P-IIa clinical trials and is being evaluated in combination with other antiviral agents for cHBV. Founded Year: 2018 Total Employees: ~80 Headquarters: California, United States Market Cap: $43.1M It is a subcutaneous RNAi therapeutic designed to reduce HBV viral antigens, including HBsAg.

HIV Treatment and Prevention Agents 40

HIV Treatment and Prevention Agents Packaging Immunization Vaccines 40

ISPE

JULY 6, 2023

1 , 4 A Retrospective Journey In 2015, Vertex’s Orkambi was the first approved drug produced under a CM process for the treatment of cystic fibrosis. Vertex continued to invest in CM with two additional approved drugs—Symdeco/Symkevi in 2018 and Trikafta in 2019—with the same indication. Published 24 September 2018. Garcia, D.

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents Dosage Pharmaceutical Companies Pharmaceutical Companies 52